# Special Combination of OBP-301 and Pembrolizumab

> **NCT03172819** · PHASE1 · COMPLETED · sponsor: **Toshihiko Doi** · enrollment: 22 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** OBP-301
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03172819
- **Lead sponsor:** Toshihiko Doi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-01
- **Primary completion:** 2021-04-06
- **Final completion:** 2022-04-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-09-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172819, "Special Combination of OBP-301 and Pembrolizumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03172819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*